市場調査レポート

商品コード

1701031

吸収不良症候群の市場規模、シェア、成長分析、原因疾患別、診断別、投与経路別、治療別、エンドユーザー別、地域別-2025～2032年産業予測

Malabsorption Syndrome Market Size, Share, and Growth Analysis, By Causative Diseases, By Diagnosis, By Route Of Administration, By Treatment, By End-User, By Region - Industry Forecast 2025-2032

出版日: 2025年04月02日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 780,584円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 913,136円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,045,688円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.28円

全表示
概要
目次

概要

サンプル依頼リストに入れる

吸収不良症候群市場規模は2023年に31億米ドルと評価され、2024年の33億1,000万米ドルから2032年には56億5,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは6.9％で成長する展望です。

世界の吸収不良症候群市場は、ライフスタイルの変化、食習慣、高齢化などの要因に起因する有病率の上昇を原動力に成長を遂げています。また、セリアック病やクローン病などの治療も、効果的な診断・治療ソリューションの需要拡大に寄与しています。強化された画像技術、バイオマーカー同定、遺伝子検査などの診断技術の顕著な進歩により、吸収不良症候群の診断精度とスピードが大幅に向上し、医療プロバイダはタイムリーな介入を開始できるようになりました。さらに、患者や医療専門家の意識の高まりにより、症状の早期発見と管理が促進されています。教育キャンペーンや情報普及の努力は、個人が速やかに医療機関を受診する力を与え、最終的に吸収不良症候群を管理する上で、より良い健康結果をもたらしています。

市場概要
画像研究
- CTスキャン
- 内視鏡的逆行性胆道膵管造影（ERCP）
- 磁気共鳴胆道膵管造影（MRCP）
- 腹部X線
血液検査
その他
- 脂肪吸収不良検査
- 炭水化物吸収検査
- シリングテスト
- D-キシロース検査
- 胆汁酸塩吸収検査
- C-D-キシロース呼気検査

吸収不良症候群市場規模：投与経路別&CAGR（2025～2032年）

市場概要
経口
保護者

吸収不良症候群市場規模：治療別&CAGR（2025～2032年）

市場概要
グルテンフリーダイエット
抗炎症薬
抗生物質
栄養補助食品
プロテアーゼとリパーゼのサプリメント
下痢止め薬
その他

吸収不良症候群市場規模：エンドユーザー別&CAGR（2025～2032年）

市場概要
病院
学術研究機関
製薬会社
栄養クリニック
その他

吸収不良症候群市場規模&CAGR（2025～2032年）

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他の欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主要市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022～2024年）
  主要企業プロファイル
  - AbbVie Inc.（米国）
  - AstraZeneca PLC（英国）
  - Bayer AG（ドイツ）
  - Eli Lilly and Company（米国）
  - GlaxoSmithKline plc（英国）
  - Pfizer Inc.（米国）
  - Sanofi（フランス）
  - Novartis AG（スイス）
  - Merck & Co., Inc.（米国）
  - DSM（オランダ）
  - Nestle Health Science（スイス）
  - Takeda Pharmaceutical Company Limited（日本）
  - Perrigo Company plc（アイルランド）
  - Lupin Pharmaceuticals, Inc.（インド）
  - Mallinckrodt Pharmaceuticals（英国）
  - Klaire Laboratories（米国）
  - National Enzyme Company（米国）
  - Organon & Co.（米国）
  - Ferring B.V.（スイス）
  - Baxter International Inc.（米国）

結論と提言

Product Code: SQMIG35D2205

Malabsorption Syndrome Market size was valued at USD 3.1 billion in 2023 and is poised to grow from USD 3.31 billion in 2024 to USD 5.65 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global Malabsorption Syndrome market is witnessing growth driven by rising prevalence attributed to factors such as lifestyle changes, dietary habits, and an aging population. Conditions like celiac disease and Crohn's disease are also contributing to increased demand for effective diagnostic and treatment solutions. Notable advancements in diagnostic technologies, including enhanced imaging techniques, biomarker identification, and genetic testing, have significantly improved the accuracy and speed of diagnosing Malabsorption Syndrome, allowing healthcare providers to initiate timely interventions. Moreover, heightened awareness among patients and healthcare professionals has fostered early detection and management of symptoms. Educational campaigns and information dissemination efforts are empowering individuals to seek medical attention promptly, ultimately leading to better health outcomes in managing Malabsorption Syndrome.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malabsorption Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malabsorption Syndrome Market Segments Analysis

Global Malabsorption Syndrome Market is segmented by Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User and region. Based on Causative Diseases, the market is segmented into Cystic Fibrosis, Parasitic Diseases, Intestinal Disorders, Lactose Intolerance, Whipple's Disease, Tropical Sprue and Others. Based on Diagnosis, the market is segmented into Imaging Studies, Hematologic Tests and Other Tests. Based on Route Of Administration, the market is segmented into Oral and Parental. Based on Treatment, the market is segmented into Gluten-Free Diet, Anti-Inflammatory Drugs, Antibiotics, Nutritional Supplements, Protease And Lipase Supplements, Antidiarrheal Agents and Others. Based on End-User, the market is segmented into Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Nutrition Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Malabsorption Syndrome Market

The increasing incidence of malabsorption syndromes, driven by shifting lifestyles, dietary habits, and an aging population, has significantly heightened the need for effective diagnostic and treatment solutions. As awareness among both healthcare professionals and patients rises, along with advancements in diagnostic technologies, the early identification and management of these disorders have become more feasible. This proactive approach has positively influenced market expansion, as the demand for innovative therapies and diagnostic tools continues to grow. Overall, the combination of these factors is propelling the growth of the malabsorption syndrome market, highlighting the importance of addressing these health challenges.

Restraints in the Malabsorption Syndrome Market

A significant constraint in the Malabsorption Syndrome market arises from the intricate and varied characteristics of malabsorption disorders, which complicate accurate diagnosis and effective treatment. Economic factors, reimbursement challenges, and inconsistencies in healthcare infrastructure across different regions further impede the delivery of optimal patient care. Moreover, the elevated costs associated with advanced diagnostic technologies and specialized treatments can limit accessibility for certain groups, ultimately affecting widespread adoption and management of these conditions. This multifaceted landscape presents notable hurdles for healthcare providers and patients alike, making it challenging to address the needs of those suffering from malabsorption syndromes effectively.

Market Trends of the Malabsorption Syndrome Market

The malabsorption syndrome market is witnessing a significant trend towards personalized medicine, emphasizing tailored diagnostic and therapeutic strategies aligned with individual patient profiles. This shift is bolstered by advancements in genetic testing and biomarker identification, enabling precise interventions that address the unique causes of malabsorption issues. Furthermore, the development of novel therapeutic modalities, including biologics and gene therapies, illustrates a commitment to innovative approaches in treatment. As healthcare evolves towards more customized care, stakeholders in the malabsorption syndrome market are increasingly focusing on leveraging these advancements to enhance patient outcomes and overall market growth.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Malabsorption Syndrome Market Size by Causative Diseases & CAGR (2025-2032)

Market Overview
Cystic Fibrosis
Parasitic Diseases
Intestinal Disorders
- Celiac Disease
- Others
Lactose Intolerance
Whipple's Disease
Tropical Sprue
Others

Global Malabsorption Syndrome Market Size by Diagnosis & CAGR (2025-2032)

Market Overview
Imaging Studies
- CT Scan
- Endoscopic Retrograde Cholangiopancreatogram (ERCP)
- Magnetic Resonance Cholangiopancreatography (MRCP)
- Abdominal X-Ray
Hematologic Tests
Other Tests
- Test Of Fat Malabsorption
- Tests Of Carbohydrate Absorption
- Schilling Test
- D-Xylose Test
- Test Of Bile Salt Absorption
- C-D-Xylose Breath Test

Global Malabsorption Syndrome Market Size by Route Of Administration & CAGR (2025-2032)

Market Overview
Oral
Parental

Global Malabsorption Syndrome Market Size by Treatment & CAGR (2025-2032)

Market Overview
Gluten-Free Diet
Anti-Inflammatory Drugs
Antibiotics
Nutritional Supplements
Protease And Lipase Supplements
Antidiarrheal Agents
Others

Global Malabsorption Syndrome Market Size by End-User & CAGR (2025-2032)

Market Overview
Hospitals
Academic And Research Institutes
Pharmaceutical Companies
Nutrition Clinics
Others

Global Malabsorption Syndrome Market Size & CAGR (2025-2032)

North America (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
- US
- Canada
Europe (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DSM (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle Health Science (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perrigo Company plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals, Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Klaire Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
National Enzyme Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Organon & Co. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring B.V. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

吸収不良症候群の市場規模、シェア、成長分析、原因疾患別、診断別、投与経路別、治療別、エンドユーザー別、地域別-2025～2032年産業予測

Malabsorption Syndrome Market Size, Share, and Growth Analysis, By Causative Diseases, By Diagnosis, By Route Of Administration, By Treatment, By End-User, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と展望

主要市場の考察

吸収不良症候群市場規模：原因疾患別&CAGR（2025～2032年）

吸収不良症候群市場規模：診断別&CAGR（2025～2032年）